Endothelial Dysfunction and Impaired l-arginine Transport in Hypertension and Genetically Predisposed Normotensive Subjects

Trends in Cardiovascular Medicine

Volumn 16, Issue 4, 2006, Pages 118-124

  Yang, Zhiyong ^a   Kaye, David M ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGININE; CARRIER PROTEIN; CAVEOLIN; CELL PROTEIN; CHLORAMPHENICOL ACETYLTRANSFERASE; CHLORAMPHENICOL ACETYLTRANSFERASE 1; CHLORAMPHENICOL ACETYLTRANSFERASE 2; CHLORAMPHENICOL ACETYLTRANSFERASE 3; CHLORAMPHENICOL ACETYLTRANSFERASE 4; CHOLESTEROL; GLYCOSPHINGOLIPID; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; STRUCTURAL PROTEIN; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

AGING; BIOACCUMULATION; BLOOD PRESSURE; CAVEOLA; CELL ADHESION; CELL COMPARTMENTALIZATION; CHEMICAL ANALYSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; GENE FUNCTION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; LEUKOCYTE ADHERENCE; MONOCYTE; MOUSE STRAIN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; POPULATION RISK; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; TRANSPORT KINETICS; VARIABLE NUMBER OF TANDEM REPEAT; VASCULAR DISEASE; WILD TYPE;

ARGININE; BIOLOGICAL TRANSPORT; ENDOTHELIUM, VASCULAR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; RISK FACTORS; VASODILATION;

EID: 33646496604     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2006.02.003     Document Type: Review

References (70)

1. Ahlers B., Parnell M., Chin-Dusting J., and Kaye D. An age-related decline in endothelial function is not associated with alterations in l-arginine transport in humans. J Hypertens 22 (2004) 321-327
2. Alp N., and Channon K. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 24 (2004) 413-420
3. Andrew P., and Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res 43 (1999) 521-531
4. Annuk M., Zilmer M., and Fellstrom B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: impact on cardiovascular disease. Kidney Int Suppl (2003) S50-S53
5. Berkowitz D., White R., Li D., et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108 (2003) 2000-2006
6. Bolotina V., Najibi S., Palacino J., et al. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 368 (1994) 850-853
7. Brancati F., Kao W., Folsom A., et al. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 283 (2000) 2253-2259
8. Bucci M., Gratton J., Rudic R., et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 6 (2000) 1362-1367
9. Calver A., Collier J., Moncada S., and Vallance P. Effect of local intra-arterial NG-monomethyl-l-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 10 (1992) 1025-1031
10. Caulfield M., Munroe P., Pembroke J., et al. Genome-wide mapping of human loci for essential hypertension. Lancet 361 (2003) 2118-2123
11. Chen P., and Sanders P. Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. Hypertension 22 (1993) 812-818
12. Cines D., Pollak E., Buck C., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91 (1998) 3527-3561
13. Closs E., Lyons C., Kelly C., and Cunningham J. Characterization of the third member of the MCAT family of cationic amino acid transporters. Identification of a domain that determines the transport properties of the MCAT proteins. J Biol Chem 268 (1993) 20796-20800
14. Closs E., Graf P., Habermeier A., et al. Human cationic amino acid transporters hCAT-1, hCAT-2A, and hCAT-2B: three related carriers with distinct transport properties. Biochemistry 36 (1997) 6462-6468
15. Cockcroft J., Chowienczyk P., Benjamin N., et al. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med 330 (1994) 1036-1040
16. De Champlain J., Wu R., Girouard H., et al. Oxidative stress in hypertension. Clin Exp Hypertens 26 (2004) 593-601
17. De Meyer G., and Herman A. Nitric oxide and vascular endothelial dysfunction. In: Ignarro L. (Ed). Nitric oxide biology and pathobiology (2000), Academic, San Diego 547-569
18. Dye J., Vause S., Johnston T., et al. Characterization of cationic amino acid transporters and expression of endothelial nitric oxide synthase in human placental microvascular endothelial cells. FASEB J 18 (2004) 125-127
19. Fernandez J., Lopez A., Wang C., et al. Transcriptional control of the arginine/lysine transporter, cat-1, by physiological stress. J Biol Chem 278 (2003) 50000-50009
20. Gaeta G., De Michele M., Cuomo S., et al. Arterial abnormalities in the offspring of patients with premature myocardial infarction. N Engl J Med 343 (2000) 840-846
21. Galbiati F., Razani B., and Lisanti M. Emerging themes in lipid rafts and caveolae. Cell 106 (2001) 403-411
22. Gold M., Bush P., and Ignarro L. Depletion of arterial l-arginine causes reversible tolerance to endothelium-dependent relaxation. Biochem Biophys Res Commun 164 (1989) 714-721
23. Guzik T., Black E., West N., et al. Relationship between the G894T polymorphism (Glu298Asp variant) in endothelial nitric oxide synthase and nitric oxide-mediated endothelial function in human atherosclerosis. Am J Med Genet 100 (2001) 130-137
24. Heller R., Unbehaun A., Schellenberg B., et al. l-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 276 (2001) 40-47
25. Hemmens B., and Mayer B. Enzymology of nitric oxide synthases. Methods Mol Biol 100 (1998) 1-32
26. Hingorani A. Endothelial nitric oxide synthase polymorphisms and hypertension. Curr Hypertens Rep 5 (2003) 19-25
27. Izawa H., Yamada Y., Okada T., et al. Prediction of genetic risk for hypertension. Hypertension 41 (2003) 1035-1040
28. Jachymova M., Horky K., Bultas J., et al. Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. Biochem Biophys Res Commun 284 (2001) 426-430
29. Jin J., Nakura J., Wu Z., et al. Association of endothelin-1 gene variant with hypertension. Hypertension 41 (2003) 163-167
30. Jones L., and Hingorani A. Genetic regulation of endothelial function. Heart 91 (2005) 1275-1277
31. Jones L., Tran C., Leiper J., et al. Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun 310 (2003) 836-843
32. Kalinowski L., Dobrucki I., and Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation 109 (2004) 2511-2517
33. Kamada Y., Nagaretani H., Tamura S., et al. Vascular endothelial dysfunction resulting from l-arginine deficiency in a patient with lysinuric protein intolerance. J Clin Invest 108 (2001) 717-724
34. Kamide K., Kokubo Y., Yang J., et al. Hypertension susceptibility genes on chromosome 2p24-p25 in a general Japanese population. J Hypertens 23 (2005) 955-960
35. Katusic Z. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role?. Am J Physiol Heart Circ Physiol 281 (2001) H981-H986
36. Kaye D., Parnell M., and Ahlers B. Reduced myocardial and systemic l-arginine uptake in heart failure. Circ Res 91 (2002) 1198-1203
37. Kim Y., Bombeck C., and Billiar T. Nitric oxide as a bifunctional regulator of apoptosis. Circ Res 84 (1999) 253-256
38. Knowles R., and Moncada S. Nitric oxide synthases in mammals. Biochem J 298 (1994) 249-258 (Pt 2)
39. Kurowska E. Nitric oxide therapies in vascular diseases. Curr Pharm Des 8 (2002) 155-166
40. Laursen J., Somers M., Kurz S., et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 103 (2001) 1282-1288
41. Li H., Meininger C., Hawker Jr. J., et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 280 (2001) E75-E82
42. Lifton R. Molecular genetics of human blood pressure variation. Science 272 (1996) 676-680
43. Linke A., Recchia F., Zhang X., and Hintze T. Acute and chronic endothelial dysfunction: implications for the development of heart failure. Heart Fail Rev 8 (2003) 87-97
44. Malinski T. Understanding nitric oxide physiology in the heart: a nanomedical approach. Am J Cardiol 96 (2005) 13i-24i
45. Mann G., Yudilevich D., and Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 83 (2003) 183-252
46. Marteau J., Zaiou M., Siest G., and Visvikis-Siest S. Genetic determinants of blood pressure regulation. J Hypertens 23 (2005) 2127-2143
47. Maxwell A., and Cooke J. Cardiovascular effects of l-arginine. Curr Opin Nephrol Hypertens 7 (1998) 63-70
48. McAllister A., Atkinson A., Johnston G., et al. Basal nitric oxide production is impaired in offspring of patients with essential hypertension. Clin Sci (Lond) 97 (1999) 141-147
49. McDonald D., Alp N., and Channon K. Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells. Pharmacogenetics 14 (2004) 831-839
50. Mein C., Caulfield M., Dobson R., and Munroe P. Genetics of essential hypertension. Hum Mol Genet 13 (2004) R169-R175 (Spec No 1)
51. Nassar B., Bevin L., Johnstone D., et al. Relationship of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and early-onset coronary artery disease. Am Heart J 142 (2001) 586-589
52. Ou W., and Silver J. Role of a conserved amino-terminal sequence in the ecotropic MLV receptor mCAT1. Virology 308 (2003) 101-113
53. Panza J., Casino P., Kilcoyne C., and Quyyumi A. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 87 (1993) 1468-1474
54. Panza J., Garcia C., Kilcoyne C., et al. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 91 (1995) 1732-1738
55. Persu A., Stoenoiu M., Messiaen T., et al. Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 11 (2002) 229-241
56. Perticone F., Sciacqua A., Scozzafava A., et al. Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. J Clin Endocrinol Metab 89 (2004) 3606-3609
57. Preli R., Klein K., and Herrington D. Vascular effects of dietary l-arginine supplementation. Atherosclerosis 162 (2002) 1-15
58. Razani B., Engelman J., Wang X., et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 276 (2001) 38121-38138
59. Schachinger V., Britten M., and Zeiher A. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906
60. Schlaich M., Parnell M., Ahlers B., et al. Impaired l-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation 110 (2004) 3680-3686
61. Schneider M., Hilgers K., Huang Y., et al. The C242T p22phox polymorphism and endothelium-dependent vasodilation in subjects with hypercholesterolaemia. Clin Sci (Lond) 105 (2003) 97-103
62. Siani A., Pagano E., Iacone R., et al. Blood pressure and metabolic changes during dietary l-arginine supplementation in humans. Am J Hypertens 13 (2000) 547-551
63. Sobrevia L., and Mann G. Dysfunction of the endothelial nitric oxide signalling pathway in diabetes and hyperglycaemia. Exp Physiol 82 (1997) 423-452
64. Stangl K., Cascorbi I., Laule M., et al. High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics 10 (2000) 133-140
65. Taddei S., Virdis A., Mattei P., et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 91 (1995) 1981-1987
66. Taddei S., Virdis A., Mattei P., et al. Defective l-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 94 (1996) 1298-1303
67. Tanira M., and Al Balushi K. Genetic variations related to hypertension: a review. J Hum Hypertens 19 (2005) 7-19
68. Tsujita Y., Baba S., Yamauchi R., et al. Association analyses between genetic polymorphisms of endothelial nitric oxide synthase gene and hypertension in Japanese: the Suita Study. J Hypertens 19 (2001) 1941-1948
69. Uwabo J., Soma M., Nakayama T., and Kanmatsuse K. Association of a variable number of tandem repeats in the endothelial constitutive nitric oxide synthase gene with essential hypertension in Japanese. Am J Hypertens 11 (1998) 125-128
70. Wu G., Flynn N., Flynn S., et al. Dietary protein or arginine deficiency impairs constitutive and inducible nitric oxide synthesis by young rats. J Nutr 129 (1999) 1347-1354